Sreechem Resins (514248)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹37.29 per share gives some tangible asset support, even though price at ₹70.98 is already 1.90x book.
• Latest quarter sales of ₹7 Cr show the business is still operating and has a revenue base to build upon.
• As a commodity chemical company, a cyclical upswing in demand or resin prices could eventually lift margins from current depressed levels.
• A small market cap of ₹30 Cr means even modest absolute improvement in profitability could have a visible per-share impact.

Concerns

• Latest quarter net loss of ₹1 Cr makes P/E meaningless; ROE at -5.05% and ROCE at -1.99% indicate value destruction.
• Sales growth of -29.69% and profit growth of -66.67% show a shrinking business with deteriorating earnings.
• Piotroski F-Score of 2/9 points to weak financial health across profitability, leverage and operating efficiency.
• At ₹70.98, the stock is at the top of its 52-week range and trades at 1.90x book despite negative returns, offering no margin of safety.
• No dividend yield and undisclosed promoter holding/debt-equity data limit income support and governance/leverage assessment.

AI Analysis

At first glance, this is exactly the kind of small-cap chemical stock that tempts Indian investors with hopes of a rebound. But I do not invest in hopes; I invest in numbers. Sreechem Resins is a commodity chemical business with no pricing power, and the numbers are poor. The latest quarter shows sales of only ₹7 crore and a net loss of ₹1 crore. Sales are down 29.69%, and profits have fallen 66.67%. With a P/E of 0.00, I cannot use the 'E' at all. Return on equity is -5.05% and ROCE is -1.99%, meaning this business is destroying value rather than compounding it. The Piotroski F-Score of 2 out of 9 reinforces that: this is not a financially healthy company. The stock trades at ₹70.98, near the top of its 52-week range of ₹28.30 to ₹70.98. That is remarkable for a loss-making business. I am asked to pay 1.90 times book value of ₹37.29 per share, but what quality of book value? A business earning negative returns on that book is not worth a premium. There is no dividend yield to compensate me while I wait. Promoter holding and debt/equity are undisclosed, so I cannot judge insider alignment or leverage. In a commodity chemical, the only moat is low cost or unique assets, and none is evident from these figures. Buffett would say it is far better to buy a wonderful business at a fair price than a poor business at any price. This is a poor business at a price that seems to anticipate a cyclical recovery that is not yet visible. I will leave it to Mr. Market's enthusiasm. If the company stabilises, generates positive earnings, improves its F-score, and offers a price well below book on a normalised earning power, I may revisit. Until then, this is a pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer